Study of cytokine-induced immunity in bullous pemphigoid: recent developments

References

• Annunziato F, Romagnani C, Romagnani S. The 3 major types of innate and adaptive cell-mediated effector immunity. J Allergy Clin Immunol. 2015;135(3):1–6. doi: 10.1016/j.jaci.2014.11.001.
   Web of Science ®Google Scholar
• Akdis CA, Arkwright PD, Brüggen MC, et al. Type 2 immunity in the skin and lungs. Allergy. 2020;75(7):1582–1605. doi: 10.1111/all.14318.
   PubMed Web of Science ®Google Scholar
• Cavani A, Pennino D, Eyerich K. Th17 and Th22 in skin allergy. Chem Immunol Allergy. 2012;96:39–44.
   PubMedGoogle Scholar
• Didona D, Scarsella L, Fehresti M, et al. Autoreactive peripheral blood T helper cell responses in bullous pemphigoid and elderly patients with pruritic disorders. Front Immunol. 2021;12:569287. doi: 10.3389/fimmu.2021.569287.
   PubMed Web of Science ®Google Scholar
• Mukhatayev Z, Ostapchuk YO, Fang D, et al. Engineered antigen-specific regulatory T cells for autoimmune skin conditions. Autoimmun Rev. 2021;20(3):102761. doi: 10.1016/j.autrev.2021.102761.
   PubMed Web of Science ®Google Scholar
• Ahmed AR, Anwar S, Reche PA. Molecular basis for global incidence of pemphigoid diseases and differences in phenotypes. Front Immunol. 2022;13:807173. doi: 10.3389/fimmu.2022.807173.
   PubMed Web of Science ®Google Scholar
• Büdinger L, Borradori L, Yee C, et al. Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls. J Clin Invest. 1998;102(12):2082–2089. doi: 10.1172/JCI3335.
   PubMed Web of Science ®Google Scholar
• Lin MS, Fu CL, Giudice GJ, et al. Epitopes targeted by bullous pemphigoid T lymphocytes and autoantibodies map to the same sites on the bullous pemphigoid 180 ectodomain. J Invest Dermatol. 2000;115(6):955–961. doi: 10.1046/j.1523-1747.2000.00153.x.
   PubMed Web of Science ®Google Scholar
• Watanabe S, Yamada Y, Murakami H. Expression of Th1/Th2 cell-related chemokine receptors on CD4(+) lymphocytes under physiological conditions. Int J Lab Hematol. 2020;42(1):68–76. doi: 10.1111/ijlh.13141.
   PubMed Web of Science ®Google Scholar
• Tanita K, Fujimura T, Sato Y, et al. Minocycline decreases Th2 chemokines from M2 macrophages: possible mechanisms for the suppression of bullous pemphigoid by traditional bullous disease drugs. Exp Dermatol. 2018;27(11):1268–1272. doi: 10.1111/exd.13779.
   PubMed Web of Science ®Google Scholar
• Nakashima H, Fujimoto M, Asashima N, et al. Serum chemokine profile in patients with bullous pemphigoid. Br J Dermatol. 2007;156(3):454–459. doi: 10.1111/j.1365-2133.2006.07601.x.
   PubMed Web of Science ®Google Scholar
• Eming R, Büdinger L, Riechers R, et al. Frequency analysis of autoreactive T-helper 1 and 2 cells in bullous pemphigoid and pemphigus vulgaris by enzyme-linked immunospot assay. Br J Dermatol. 2000;143(6):1279–1282. doi: 10.1046/j.1365-2133.2000.03901.x.
   PubMed Web of Science ®Google Scholar
• De Bruyn Carlier T, Badloe FMS, Ring J, et al. Autoreactive T cells and their role in atopic dermatitis. J Autoimmun. 2021;120:102634. doi: 10.1016/j.jaut.2021.102634.
   PubMed Web of Science ®Google Scholar
• Kridin K, Hammers CM, Ludwig RJ, et al. The association of bullous pemphigoid with atopic dermatitis and allergic rhinitis—a population-based study. Dermatitis. 2022;33(4):268–276. doi: 10.1097/DER.0000000000000792.
   PubMed Web of Science ®Google Scholar
• Tabatabaei-Panah PS, Moravvej H, Alirajab M, et al. Association between TH2 cytokine gene polymorphisms and risk of bullous pemphigoid. Immunol Invest. 2022;51(2):343–356. doi: 10.1080/08820139.2020.1832113.
   PubMed Web of Science ®Google Scholar
• Shen J, Yuan HJ, Pan M. The role of eosinophils in the pathogenesis of bullous pemphigoid. Chin J Dermatol. 2019;52(8):579–581.
   Google Scholar
• Jones VA, Patel PM, Amber KT. Eosinophils in bullous pemphigoid. Panminerva Med. 2021;63(3):368–378. doi: 10.23736/S0031-0808.20.03997-X.
   PubMed Web of Science ®Google Scholar
• Russo R, Cozzani E, Gasparini G, et al. Targeting interleukin 4 receptor α: a new approach to the treatment of cutaneous autoimmune bullous diseases? Dermatol Ther. 2020;33(1):e13190.
   PubMed Web of Science ®Google Scholar
• Günther C, Carballido-Perrig N, Kopp T, et al. CCL18 is expressed in patients with bullous pemphigoid and parallels disease course. Br J Dermatol. 2009;160(4):747–755. doi: 10.1111/j.1365-2133.2008.08979.x.
   PubMed Web of Science ®Google Scholar
• Karo-Atar D, Bitton A, Benhar I, et al. Therapeutic targeting of the interleukin-4/interleukin-13 signaling pathway: in allergy and beyond. BioDrugs. 2018;32(3):201–220. doi: 10.1007/s40259-018-0280-7.
   PubMed Web of Science ®Google Scholar
• Pickford WJ, Gudi V, Haggart AM, et al. T cell participation in autoreactivity to NC16a epitopes in bullous pemphigoid. Clin Exp Immunol. 2015;180(2):189–200. doi: 10.1111/cei.12566.
   PubMed Web of Science ®Google Scholar
• Zhang J, Fang H, Shen S, et al. Identification of immunodominant Th2-cell epitopes in Chinese patients with bullous pemphigoid. J Invest Dermatol. 2018;138(9):1917–1924. doi: 10.1016/j.jid.2018.03.1515.
   PubMed Web of Science ®Google Scholar
• Gounni Abdelilah S, Wellemans V, Agouli M, et al. Increased expression of Th2-associated chemokines in bullous pemphigoid disease. Role of eosinophils in the production and release of these chemokines. Clin Immunol. 2006;120(2):220–231. doi: 10.1016/j.clim.2006.03.014.
   PubMed Web of Science ®Google Scholar
• Afarideh M, Borucki R, Werth VP. A review of the immunologic pathways involved in bullous pemphigoid and novel therapeutic targets. J Clin Med. 2022;11(10):2856. doi: 10.3390/jcm11102856.
   PubMed Web of Science ®Google Scholar
• Cirillo N, Prime SS. A scoping review of the role of metalloproteinases in the pathogenesis of autoimmune pemphigus and pemphigoid. Biomolecules. 2021;11(10):1506. doi: 10.3390/biom11101506.
   PubMed Web of Science ®Google Scholar
• Kowalski EH, Kneibner D, Kridin K, et al. Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid. Autoimmun Rev. 2019;18(5):526–534. doi: 10.1016/j.autrev.2019.03.009.
   PubMed Web of Science ®Google Scholar
• Kabuto M, Fujimoto N, Takahashi T, et al. Decreased level of interleukin-10-producing B cells in patients with pemphigus but not in patients with pemphigoid. Br J Dermatol. 2017;176(5):1204–1212. doi: 10.1111/bjd.15113.
   PubMed Web of Science ®Google Scholar
• Antiga E, Quaglino P, Volpi W, et al. Regulatory T cells in skin lesions and blood of patients with bullous pemphigoid. J Eur Acad Dermatol Venereol. 2014;28(2):222–230. doi: 10.1111/jdv.12091.
   PubMed Web of Science ®Google Scholar
• Liu Z, Dang E, Li B, et al. Dysfunction of CD19(+)CD24(hi)CD27(+) B regulatory cells in patients with bullous pemphigoid. Sci Rep. 2018;8(1):703. doi: 10.1038/s41598-018-19226-z.
   PubMedGoogle Scholar
• Riani M, Muller C, Bour C, et al. Blister fluid induces MMP-9-associated M2-type macrophages in bullous pemphigoid. Front Immunol. 2019;10:1858. doi: 10.3389/fimmu.2019.01858.
   PubMed Web of Science ®Google Scholar
• Berkani N, Joly P, Golinski ML, et al. B-cell depletion induces a shift in self antigen specific B-cell repertoire and cytokine pattern in patients with bullous pemphigoid. Sci Rep. 2019;9(1):3525. doi: 10.1038/s41598-019-40203-7.
   PubMedGoogle Scholar
• Wang Y, Mao X, Liu Y, et al. IL-13 genetic susceptibility to bullous pemphigoid: a potential target for treatment and a prognostic marker. Front Immunol. 2022;13:824110. doi: 10.3389/fimmu.2022.824110.
   PubMed Web of Science ®Google Scholar
• Bridgewood C, Sharif K, Freeston J, et al. Regulation of entheseal IL-23 expression by IL-4 and IL-13 as an explanation for arthropathy development under dupilumab therapy. Rheumatology. 2021;60(5):2461–2466. doi: 10.1093/rheumatology/keaa568.
   PubMed Web of Science ®Google Scholar
• Zhou T, Peng B, Geng S. Emerging biomarkers and therapeutic strategies for refractory bullous pemphigoid. Front Immunol. 2021;12:718073. doi: 10.3389/fimmu.2021.718073.
   PubMed Web of Science ®Google Scholar
• Cozzani E, Gasparini G, Di Zenzo G, et al. Immunoglobulin E and bullous pemphigoid. Eur J Dermatol. 2018;28(4):440–448. doi: 10.1684/ejd.2018.3366.
   PubMed Web of Science ®Google Scholar
• Xiong H, Dolpady J, Wabl M, et al. Sequential class switching is required for the generation of high affinity IgE antibodies. J Exp Med. 2012;209(2):353–364. doi: 10.1084/jem.20111941.
   PubMed Web of Science ®Google Scholar
• Boehncke WH, Brembilla NC. Autoreactive T-lymphocytes in inflammatory skin diseases. Front Immunol. 2019;10:1198. doi: 10.3389/fimmu.2019.01198.
   PubMed Web of Science ®Google Scholar
• Bao L, Li J, Solimani F, et al. Subunit-specific reactivity of autoantibodies against laminin-332 reveals direct inflammatory mechanisms on keratinocytes. Front Immunol. 2021;12:775412. doi: 10.3389/fimmu.2021.775412.
   PubMed Web of Science ®Google Scholar
• Kridin K, Ludwig RJ, Tzur Bitan D, et al. A history of asthma increases the risk of bullous pemphigoid: insights from a large population-based study. Dermatology. 2021;237(6):921–928. doi: 10.1159/000512917.
   PubMed Web of Science ®Google Scholar
• Tabatabaei-Panah PS, Moravvej H, Aghaei S, et al. TH17/IL23 cytokine gene polymorphisms in bullous pemphigoid. Mol Genet Genomic Med. 2020;8(12):e1519.
   PubMed Web of Science ®Google Scholar
• Hsieh CY, Tsai TF. Management of coexisting bullous pemphigoid and psoriasis: a review. Am J Clin Dermatol. 2022;23(6):869–879. doi: 10.1007/s40257-022-00719-7.
   PubMed Web of Science ®Google Scholar
• Giusti D, Bini E, Terryn C, et al. NET formation in bullous pemphigoid patients with relapse is modulated by IL-17 and IL-23 interplay. Front Immunol. 2019;10:701. doi: 10.3389/fimmu.2019.00701.
   PubMed Web of Science ®Google Scholar
• Chakievska L, Holtsche MM, Künstner A, et al. IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid. J Autoimmun. 2019;96:104–112. doi: 10.1016/j.jaut.2018.09.003.
   PubMed Web of Science ®Google Scholar
• Plée J, Le Jan S, Giustiniani J, et al. Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcome. Sci Rep. 2015;5(1):18001. doi: 10.1038/srep18001.
   PubMedGoogle Scholar
• Leijs M, Fietkau K, Merk HF, et al. Upregulation of CCL7, CCL20, CXCL2, IL-1β, IL-6 and MMP-9 in skin samples of PCB exposed individuals—a preliminary study. Int J Environ Res Public Health. 2021;18(18):9711. doi: 10.3390/ijerph18189711.
   PubMed Web of Science ®Google Scholar
• De Graauw E, Sitaru C, Horn M, et al. Evidence for a role of eosinophils in blister formation in bullous pemphigoid. Allergy. 2017;72(7):1105–1113. doi: 10.1111/all.13131.
   PubMed Web of Science ®Google Scholar
• Britt RD, Thompson MA, Sasse S, et al. Th1 cytokines TNF-α and IFN-γ promote corticosteroid resistance in developing human airway smooth muscle. Am J Physiol Lung Cell Mol Physiol. 2019;316(1):L71–L81. doi: 10.1152/ajplung.00547.2017.
   PubMed Web of Science ®Google Scholar
• Wang Z, Wang C, Wang Y, et al. E4BP4 facilitates glucocorticoid sensitivity of human bronchial epithelial cells via down-regulation of glucocorticoid receptor-beta. Cell Immunol. 2018;334:31–37. doi: 10.1016/j.cellimm.2018.08.015.
   PubMed Web of Science ®Google Scholar
• Vazquez-Tello A, Halwani R, Hamid Q, et al. Glucocorticoid receptor-beta up-regulation and steroid resistance induction by IL-17 and IL-23 cytokine stimulation in peripheral mononuclear cells. J Clin Immunol. 2013;33(2):466–478. doi: 10.1007/s10875-012-9828-3.
   PubMed Web of Science ®Google Scholar
• Cao P, Xu W, Zhang L. Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: a systematic review. Front Immunol. 2022;13:928621. doi: 10.3389/fimmu.2022.928621.
   PubMed Web of Science ®Google Scholar
• Simon D, Yousefi S, Cazzaniga S, et al. Mepolizumab failed to affect bullous pemphigoid: a randomized, placebo-controlled, double-blind phase 2 pilot study. Allergy. 2020;75(3):669–672. doi: 10.1111/all.13950.
   PubMed Web of Science ®Google Scholar